Left ventricular (LV) ejection fraction (EF) and right ventricular (RV) ejection fraction by cardiovascular magnetic resonance (CMR) are associated with functional health status in patients with repaired tetralogy of Fallot (TOF) in cross-sectional studies, but few longitudinal data are available. This study aimed to determine predictors of subsequent decrease in functional health status in midterm follow-up. Patients with repaired TOF who had previously completed CMR and assessment with the Short Form 36 version 2 (SF-36) were recruited for repeat CMR, SF-36, and exercise test, if they had not had interval pulmonary valve replacement (PVR). Patients from the same cohort who had undergone PVR were recruited for repeat SF-36. A total of 19 patients (median 33.5 years old, interquartile range [IQR] 26-42 years, 53 % male) had not undergone PVR and were enrolled at a median of 5.0 years (IQR 4.8-5.3) since prior CMR and SF-36. LVEF and RVEF did not change from baseline, while RV end-diastolic volume increased (138 ± 34 vs. 126 ± 31 ml/m 2 , p = 0.02). In the overall cohort, SF-36 scores remained stable. However, higher baseline RV end-systolic volume and pulmonary regurgitant fraction correlated with subsequent decreases in SF-36 scores. In 9 patients post-PVR (median 35.9 years old, IQR 24-43), physical functioning increased compared to those without PVR (change in z-score ?0.59 ± 0.59 vs.
Introduction
After repair of tetralogy of Fallot (TOF), chronic pulmonary insufficiency is typical and may lead to right ventricular (RV) dilatation, with subsequent right and left ventricular (LV) dysfunction [1] . RV dilatation and LV and RV dysfunction are associated with negative clinical outcomes such as death, sustained ventricular tachycardia, and progression to New York Heart Association Class III-IV [2] [3] [4] [5] . Although pulmonary valve replacement (PVR) decreases RV volume overload and may alter ventricular mechanics, it is unclear whether PVR alters the natural history and which patients will benefit. RV end-systolic volume has been proposed in algorithms for decision making in timing of PVR [1] , as it reflects a combination of RV dilatation and RV systolic function, but studies have largely used surrogate outcomes of ''normalization'' of RV size and systolic function [6] [7] [8] .
In cross-sectional studies, patient-reported functional health status, as characterized by the Short Form 36 version 2 (SF-36), is slightly lower than controls and is related to ventricular dysfunction [9] [10] [11] , but few longitudinal data are available. This study aimed to determine predictors of subsequent decrease in functional health status in midterm follow-up in this population.
Methods
A previous cohort with repaired TOF had been recruited to complete cardiovascular magnetic resonance (CMR) and the SF-36 from 2008 to 2009 [9] . Patients from the previous cohort were excluded if they had died in the interval, had a pacemaker or defibrillator implanted, or had completed the initial SF-36 more than 6 months from the baseline CMR. Patients who had not undergone interval PVR were contacted and recruited for repeat CMR, exercise test, and SF-36 from September 2013 through November 2014, and comprised Group I. Patients who had undergone PVR (Group II) were also recruited to complete the SF-36 for comparison. Repeat CMR was not performed in Group II, as change in CMR parameters has been well documented, related to change in hemodynamics after PVR [1] . All patients provided informed consent, and this study was approved by the institutional review board at the University of Michigan.
Functional Health Status
The SF-36 is a 36-question survey that assesses patientreported health status and has been validated in multiple patient populations [12] . Eight subscales are evaluated; for the purposes of this study, 3 subscales were chosen to evaluate the physical impact of disease. Physical functioning (PF) assesses the ability to perform physical activities. Role-physical (RP) assesses the ability to participate in work or usual activities without physical limitations. General health (GH) assesses patient perception of general health and its likelihood to change. In addition, two summary scores are generated, the physical component summary score (PCS) and the mental component summary score. Patients in Group I completed the SF-36 on the same day as exercise test and CMR; patients in Group II completed the SF-36 when enrolled. Age-adjusted z-scores were based on normative data in the general population [12] .
Cardiovascular Magnetic Resonance
CMR was performed on a 1.5 Tesla scanner (Achieva or Ingenia, Philips, Best, The Netherlands). Cine images were obtained with a breath hold, vectorcardiographic gated, segmented k-space, steady-state free precession sequence, with 30 phases per cardiac cycle. LV and RV end-diastolic volume (EDV), end-systolic volume (ESV), ejection fraction (EF), and mass were measured in the short-axis plane (QMass, Medis, Leiden, The Netherlands). Phase contrast imaging was performed orthogonal to the main pulmonary artery using a free breathing, vectorcardiographic gated, velocity-encoded sequence with 40 phases per cardiac cycle.
LV and RV strain measurements were taken by a single observer blinded to volumetric data, using feature tracking software (Cardiac Performance Analysis, Tomtec, Unterschleissheim, Germany). Points were manually selected along the endocardial contour, with subsequent automated tracking. Contours were visually evaluated for adequate tracking and redrawn as necessary. LV circumferential strain was measured from a mid-ventricular short-axis slice. LV longitudinal strain and RV longitudinal strain were measured from a 4-chamber slice.
Exercise Capacity
Patients in Group I underwent exercise treadmill test with the modified Bruce protocol on the same day as CMR. Peak oxygen consumption and exercise duration were evaluated with SF-36 data from the same day.
Statistical Analysis
Data are presented as frequency (percent), mean ± SD, or median (interquartile range [IQR]) as appropriate. Baseline characteristics and change in CMR parameters and SF-36 assessments after baseline were compared between groups using Student's t test (if normally distributed) or Wilcoxon rank sum for continuous variables and Fisher's exact test for categorical variables. Changes in CMR parameters and SF-36 assessments from baseline to follow-up in Group I were examined using paired t test. Correlation between continuous variables was evaluated using Pearson correlation coefficient (if normally distributed) or Spearman's correlation coefficient. Two-tailed p value \0.05 was considered statistically significant. All analyses were performed using SAS, version 9.4 (SAS Institute, Cary, NC).
Results
A total of 28 patients were enrolled at a median 5.0 years (IQR 4.7-5.3) after initial assessment. Group I consisted of 19 patients who had not undergone PVR; Group II consisted of 9 eligible patients who underwent interval PVR ( Fig. 1 ). Demographics and baseline characteristics are presented in Table 1 . Patients enrolled in Group I had no significant differences in demographics, baseline CMR parameters or baseline SF-36 scores from patients who did not enroll (data not shown). As expected, patients in Group II had higher baseline RVEDV and pulmonary regurgitant fraction, but baseline RVEF and LVEF were similar.
Changes in Ventricular Volume and Function
In Group I, in the absence of PVR, RVEDV increased, while LVEF, RVEF, and RV mass were stable (Fig. 2 ). There was no correlation between subsequent changes in RVEDV with baseline RVEDV (r = -0.21, p = 0.40), RVESV (r = -0.01, p = 0.97), indexed RV mass (r = -0.04, p = 0.87), RVEF (r = -0.35, p = 0.14), RV longitudinal strain (r = -0.05, p = 0.83), LVEF (r = -0.39, p = 0.10), LV circumferential strain (r = 0.21, p = 0.39), LV longitudinal strain (r = 0.33, p = 0.17), or pulmonary regurgitant fraction (r = -0.37, p = 0.12).
Functional Health Status
SF-36 scores in the overall cohort were within the normal range and were stable from baseline ( Fig. 3 ). Exercise treadmill test was completed by 16/19 (84 %) patients in Group I, with peak oxygen consumption 23.3 ± 4.9 ml/kg/ min and endurance 9.8 ± 2.2 min. Exercise endurance positively correlated with GH score (r = 0.52, p = 0.04), with a nonsignificant trend between peak oxygen consumption and PF score (r = 0.43, p = 0.10).
In Group I, baseline RVESV and pulmonary regurgitant fraction were associated with subsequent change in SF-36 scores, while baseline RVEDV, LVEF, RVEF, RV mass and RV mass/volume ratio were not ( Table 2) . Indexed pulmonary regurgitant volume showed a similar trend to regurgitant fraction (r = -0.43 for PF, p = 0.07, and r = -0.41 for RP, p = 0.08), but did not reach statistical significance. Baseline strain measurements did not correlate with change in SF-36 scores. Prior to PVR, patients in Group II trended toward lower SF-36 scores than patients in Group I at baseline, although differences did not meet statistical significance (PCS ageadjusted z-score -0.8 ± 1.5 vs. -0.1 ± 0.6, p = 0.20, PF -1.0 ± 1.5 vs. -0.1 ± 0.9, p = 0.054, RP -0.6 ± 1.6 vs. 0.2 ± 0.8, p = 0.18, GH -0.9 ± 1.2 vs. -0.1 ± 0.8, p = 0.06). After PVR, patients in Group II had greater improvement in PF scores than patients in Group I (Fig. 4 ). Only 1/9 patients in Group II (11.1 %) had a decrease in PF score, while 12/19 patients in Group I (63.2 %) had a decrease in PF score (p = 0.02). There were no differences in SF-36 scores between Group I and Group II patients at follow-up.
Discussion
In this cohort of adults with repaired TOF who did not undergo PVR, overall functional health status, LVEF and RVEF were fairly stable on midterm follow-up, while RVEDV increased. Elevated baseline RVESV predicts subsequent decrease in patient-reported health status. Patients status post-PVR had some increases in functional health status, with return to similar scores as the remainder of the cohort. This study adds to the existing data on the importance of RVESV for prognostication in this cohort and suggests that selected patients may demonstrate gains in functional health status with intervention.
Increase in RVEDV at midterm follow-up further supports the need for serial CMR evaluation in this cohort. The inability to predict subsequent dilatation based on the initial study, including potential early indicators of dysfunction such as strain, could be related to inadequate power. However, it is concerning that no predictors have been identified in this population to date, and serial evaluation should be recommended for all patients with repaired TOF. The INDICATOR cohort demonstrated very small but significant progressive changes in RVEDV, RVEF, and LVEF, with an optimal interval of evaluation of 3 years [13] . The current cohort had a longer interval of 5 years, but a much smaller sample size, which may explain why significant changes in LVEF and RVEF were not detected. Severe aortic regurgitation with progressive LV dilatation is a Class IIb indication for aortic valve replacement [14] ; the potential role for progressive RV dilatation (rather than an absolute RVEDV cutoff volume) in decision making for PVR, as well as a cutoff for rate of dilatation, has yet to be defined.
RV end-systolic volume is a composite measure reflecting both the degree of dilatation (RV end-diastolic volume) and systolic dysfunction (RVEF). From a pathophysiologic standpoint, increased RVESV leads to increased end-systolic wall stress, the true afterload of the ventricle, and thus, increasing RVESV may be a harbinger of subsequent ventricular dysfunction. LV end-systolic volume is a well-known prognostic indicator in adults with aortic regurgitation [14] . In patients with repaired TOF and pulmonary regurgitation, RVESV can predict a surrogate [5] , but few data exist on clinical outcomes [7] . The correlation with functional health status underscores the value of RVESV for prognostication, and potentially for decision making for intervention.
Although concrete outcomes such as mortality would be preferable, outcomes after PVR (including mortality) are excellent, and differences would be difficult to detect. Since the optimal timing of PVR is unclear, patient-centered metrics, such as functional health status, are significant in discussion of intervention. It would be premature to conclude that PVR improves functional health status, given the small sample size and non-randomized patient selection. Furthermore, assessment of health status can be affected by patient perception and expectation. Patients after PVR may be motivated to report higher functional health status, after consenting for and undergoing surgery.
However, the correlation between general health subscale scores and the more objective measure of exercise endurance (which also demonstrated a trend with physical functioning scores), suggests that this is not simply a subjective phenomenon. The key will be preoperative identification of which patients may benefit.
This study has several limitations. Loss to follow-up and difficulty in contacting patients are unfortunate limitations in the adult congenital heart disease population, which limited the sample size. However, the majority of eligible patients who did not undergo PVR, the primary target population, were enrolled and did not differ in baseline characteristics from those who did not enroll. The small sample size limits the generalizability of the findings. However, the detected differences despite the small sample size suggest an important finding, which should be confirmed by larger, multicenter studies. The decision to proceed with PVR was made by the clinicians and was not randomized. However, this reflects current clinical practice.
In summary, in patients with repaired TOF, RV dilatation progresses in midterm follow-up without intervention, while RV and LV systolic function and functional health status remain stable. Although progressive RV dilatation could not be predicted by baseline CMR, subsequent decrease in functional health status could be predicted by baseline RV end-systolic volume, which should be considered when assessing need for intervention. Further studies are necessary to confirm these findings in larger cohorts and to determine which patients can most benefit from pulmonary valve replacement. 
